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ticosteroids (steroids) are widely used
for sepsis patients. However, the
potential benefits and harms of both
high and low dose steroids remain
unclear. A systematic review of ran-
domised clinical trials with meta-
analysis and trial sequential analysis
(TSA) might shed light on this clini-
cally important question.
Methods: A systematic review was
conducted according to a published
protocol and The Cochrane Hand-
book methodology including meta-
analyses, TSA of randomised clinical
trials, and external validity estimation
(GRADE). Randomised clinical trials
evaluating steroids were included for
sepsis patients (systemic inflamma-
tory response syndrome, sepsis,
severe sepsis or septic shock) aged
[18 years. Cochrane Central Regis-
ter of Controlled Trials (CENTRAL),
PubMed/Medline, Embase, Web of
Science and Cinahl were searched
until 18 February 2015. No language
restrictions were applied. Primary
outcomes were mortality at longest
follow-up and serious adverse events.
Results: A total of 35 trials ran-
domising 4682 patients were assessed
and reviewed in full text. All trials but
two had high risk of bias. No statis-
tically significant effect was found for
any dose of steroids versus placebo or
no intervention on mortality at max-
imal follow-up [relative risk (RR)
0.89; TSA adjusted confidence inter-
val (CI) 0.74–1.08]. Two trials with
low risk of bias also showed no sta-
tistically significant difference
(random-effects model RR 0.38,
95 % CI 0.06–2.42). Similar results
were obtained in subgroups of trials
stratified according to high
([500 mg) or low (B500 mg) dose
hydrocortisone (or equivalent) (RR
0.87; TSA-adjusted CI 0.38–1.99; and
RR 0.90; TSA-adjusted CI 0.49–1.67,
respectively). There were also no
statistically significant effects on
serious adverse events other than
mortality (RR 1.02; TSA-adjusted CI
0.7–1.48). The effects did not vary
according to the degree of sepsis.
TSA showed that many more ran-
domised patients are needed before
definitive conclusions may be drawn.
Conclusion: Evidence to support or
negate the use of steroids in any dose
in sepsis patients is lacking. The
results of ongoing and future well-
designed, large randomised clinical
trials are needed.
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Introduction
In the intensive care unit (ICU), up to 25 % of admissions
are related to sepsis and an additional 12 % of patients
develop sepsis during their stay [1]. Sepsis and, if dete-
riorating, septic shock have a high morbidity and
mortality. Depending on the definition of sepsis, mortality
varies from 27 to 54 % [1]. To decrease this high rate of
morbidity and mortality, several interventions have been
suggested. Bundled interventions, like those of the Sur-
viving Sepsis Campaign [2], aim to improve outcome of
patients by, among others, early antibiotics, glucocorti-
costeroids (steroids) and supportive care.
Based on supposed pathophysiological mechanisms,
two rationales for steroids in sepsis have been put for-
ward. The first rationale is that high dose steroids may
suppress the excess in inflammatory response in sepsis. In
the 1970s and the early 1980s high dose steroids (30 mg/
kg methylprednisolone or equivalent dose) were used in
sepsis [3]. In the late 1980s the use declined on the basis
of negative results of randomised clinical trials [3];
however, in some centres, high dose steroids are still used
in clinical practice today. The second rationale, intro-
duced in the 1990s, is that low dose steroids may recover
a relative adrenal insufficiency [4]. Many trials have been
conducted, but the pathophysiological basis of the second
rationale is still questioned [5]. Possibly both high and
low dose steroids can have beneficial or harmful effects in
sepsis.
Despite the lack of evidence for the underlying
mechanism, the use of low doses of 200–300 mg hydro-
cortisone is recommended in patients with septic shock
not responding to fluid and vasopressor therapy [2]. This
recommendation is likely based on results of one sys-
tematic review, which found a statistically significant
16 % relative risk reduction (RRR) of mortality (relative
risk 0.84; unadjusted 95 % confidence interval 0.72–0.97)
in favour of prolonged low dose steroids [6]. The bene-
ficial effect found might be a subgroup effect in more
severely ill patients, a spurious finding due to a type I
random error as a consequence of repetitive testing as the
information size required for showing a 16 % RRR was
far from being reached, or an overestimation of a treat-
ment effect due to bias and suboptimal trial methodology
[7–12].
A sound methodology in a systematic review is as
important as in any type of study to avoid critical errors in
the analyses and conclusions [13]. We therefore decided
to conduct a new systematic review evaluating the effects
of steroids for sepsis in patients with systemic inflam-
matory response syndrome (SIRS), sepsis, severe sepsis
or septic shock as previous meta-analyses fall short on
several aspects of rigorous methodology.
Objective
The objective was to perform a systematic review
according to a published protocol following guidelines
from PRISMA [14] and The Cochrane Handbook for
Systematic Reviews of Interventions [15]. We also plan-
ned to execute meta-analyses and trial sequential analyses
(TSA) of randomised clinical trials that compared the
benefits and harms of high and/or low dose steroids for
patients with SIRS, sepsis, severe sepsis or septic shock.
Our primary outcome was mortality at longest follow-up
and serious adverse events.
Available evidence was to be evaluated in the per-
spective of the three dimensions of possible risks of
errors: systematic errors (bias), design errors (also leading
to systematic errors due to outcomes, comparators, etc.)
and random errors (‘the play of chance’) [16].
Methods
The systematic review was conducted following the rec-
ommendations of The Cochrane Handbook for Systematic
Reviews of Interventions [15] and reported according to
the PRISMA statement (www.prisma-statement.org). The
protocol was published on PROSPERO (http://www.crd.
york.ac.uk/PROSPERO, ID: CRD42013005617).
In addition to an overall analysis including all doses,
two separate analyses were conducted of high and low
dose steroids. The cut-off value of high and low dose
steroids was chosen arbitrarily. High doses were defined
as daily doses of more than 500 mg hydrocortisone; low
doses were defined as a daily intake of equal or less than
500 mg. Other steroids were recalculated into the equiv-
alent hydrocortisone dose [17]. When doses were
expressed in milligram per kilogram body weight, doses
were calculated assuming a body weight of 75 kg.
Eligibility criteria
Randomised clinical trials that included adult patients (age
[18 years) with SIRS, sepsis, severe sepsis or septic
shock, or any combinations thereof (Table S1). Trials
with patients with SIRS were excluded when SIRS cri-
teria were not explicitly described in their methods
section. Trials were also excluded when evaluating ster-
oids for the prevention of the occurrence of SIRS. No
limitations were made regarding underlying cause of ill-
ness. There were no restrictions on duration of treatment
(days) or whether administration occurred continuously or
intermittently. All types of steroids were included.
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Trials were included independently of the type of
control intervention: placebo, no intervention, or any
other control intervention. Co-interventions were allowed
provided that similar administration occurred in the
intervention groups. Trials were included irrespective of
chosen outcomes. No limitations were made on the basis
of language or publication status. The following study
types were excluded: quasi-randomised studies, observa-
tional studies, cross-over studies, and studies comparing
different doses or different types of steroids in both trial
intervention groups.
Search strategy
We searched the Cochrane Central Register of Controlled
Trials (CENTRAL) in The Cochrane Library, PubMed/
Medline, Embase, Web of Science and Cinahl. We also
hand-searched the reference lists of included trials and
systematic reviews for further trials. Ongoing trials were
sought through trial registries (www.clinicaltrials.gov,
www.controlled-trails.com, www.centerwatch.com). No
time restrictions were applied. The electronic literature
search strategies are listed in Table S2.
Study selection and data extraction
Two authors independently reviewed all identified titles
and abstracts and excluded clearly irrelevant hits. The
remaining hits were evaluated in full text. Disagreements
were resolved through discussion and the hits excluded on
the basis of full text were all listed.
Characteristics of patients and trials and data for
analyses were extracted by two authors independently
from the included reports. A summary of the recorded
patient data is presented in Table 1. A thorough recording
of patient data is listed in Table S5.
We contacted corresponding authors for unreported
data.
Outcomes
Primary outcomes were mortality at longest follow-up
and serious adverse events. Serious adverse events were a
composite outcome, summarizing all serious events
excluding mortality, necessitating an intervention, oper-
ation or prolonged hospital stay.
Secondary outcomes were persistent dependence on
haemodialysis and duration of mechanical ventilation.
Additionally, time-specific analyses of mortality at 30 and
90 days were conducted as secondary outcomes accord-
ing to availability of data. Data of trials reporting 28-day
mortality were included in 30-day mortality analyses. All
outcomes were classified according to the patients’
perspective according to GRADE Working Group
(Table S3) [18]. Although used in previous trials and
meta-analyses, shock reversal was not considered, as it is
a surrogate outcome, which is not important according to
the patients’ perspective [19].
Risk of bias assessment
We assessed the risk of bias according to The Cochrane
Handbook for Systematic Reviews of Interventions [15],
including all eight domains: random sequence generation,
allocation concealment, blinding of participants and per-
sonnel, blinding of outcome assessment, incomplete
outcome data, selective reporting, and other bias (aca-
demic or funding bias). If one or more of the domains
were judged as having high or unclear risk of bias, the
trial was classified as having a high risk of bias. Only two
trials had low risk of bias (in all domains) with a pooled
information size of 591 patients (nearly all data came
from one trial [20]). Therefore, we formulated a group of
trials with lower risk of bias. These trials had at least low
risk of bias in sequence generation, allocation conceal-
ment, blinding of participants and personnel, and blinding
of outcome assessment. This does not, however, exclude
risk of bias from other domains.
Statistical analysis
Review Manager 5.1.6 was used for statistical analyses.
We used the TSA program version 0.9 beta
(www.ctu.dk/tsa; [21]) to control random errors and
assess imprecision. For each included trial we calculated
the relative risk (RR) with 95 % confidence intervals (CI)
for dichotomous outcomes. We report risk differences if
statistically significant different from relative risk. We
calculated the numbers needed to treat or numbers needed
to harm with 95 % CI based on a statistically significant
RR.
Heterogeneity among trials was explored by the Chi-
squared test with significance set at P value of 0.10, and
quantified with inconsistency factor (I2) statistics. We
reported the results from the random-effects model
anticipating abundant clinical heterogeneity (in popula-
tions, interventions and settings). We reported the results
from a fixed-effect model if one or two trials dominated
the available evidence [22].
The following subgroup analyses were planned: (1)
the stratification of bias risk of trials (lower risk of bias
compared to high risk of bias); (2) the duration of steroid
treatment [long-term (C4 days) compared to short-term
(\4 days) use]; (3) patients with SIRS or sepsis compared
to patients with severe sepsis or septic shock; (4) strati-
fication based on the aetiology of sepsis; (5) trials using




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































steroid possessing mineralocorticoid properties (unlike
dexamethasone).
Trial sequential analysis
We conducted trial sequential analysis (TSA). Conven-
tional meta-analysis runs the risks of random errors due to
sparse data and repetitive testing [15, 18]. TSA adjusts the
confidence intervals, if data are sparse or repeatedly
analysed as a result of multiple updates, to allow firm
conclusions. TSA is similar to interim analysis in a single
trial where monitoring boundaries are used to decide
whether the trial should be terminated early or whether
the confidence interval and the adjacent P value are suf-
ficiently narrow or small respectively to show the
anticipated effect [23]. In the same manner, trial
sequential monitoring boundaries can be applied to meta-
analyses [9–12, 24].
TSA depends on the quantification of the required
information size. We calculated a diversity-adjusted (D2)
required information size, since the heterogeneity
adjustment with I2 underestimates the required informa-
tion size [25]. TSA was conducted with the intention to
maintain an overall 5 % risk of a type I error and a power
of 90 %. For the calculation of the required information
size, we anticipated an intervention effect of a 10 % RRR
using the control event proportion calculated from the
actual meta-analyses. We provided the TSA-adjusted CI
for sparse data and repetitive testing, which we described
as the trial sequential analysis adjusted CI. We also per-
formed sensitivity analyses with a power of 80 % and
assuming a 20 % RRR.
Grade assessment of outcomes
Data on the outcomes of all trials were assessed for the
risk of bias measured by the level of evidence, the risk of
random error measured by standard error, and the design
error measured by grading the outcomes according to
GRADE [16, 26]. Data were presented in a three-di-
mensional Manhattan error matrix that facilitates the
overview of available evidence at a glance and may
identify possible lacunae [16]. A GRADE assessment of
all outcomes considering risk of bias, inconsistency,
imprecision and risk of publication bias was conducted as
well [22].
Results
The search retrieved 5366 hits (Fig. S1). A total of 48
articles were included describing 35 distinct randomised
clinical trials. One ongoing trial was identified [27]. Two
papers were translated from Chinese by a native Chinese
medical doctor. The excluded trials and reasons for
exclusion are listed (Table S4).
Characteristics of trials
Thirty-five randomised trials were included. Fourteen
trials evaluated high dose ([500 mg hydrocortisone or
equivalent) steroids and 21 trials used low dose (B500 mg
hydrocortisone or equivalent) steroids (Table 1 and
Table S5). Fifteen trials included patients with septic
shock and two trials included patients with SIRS. Dura-
tion of steroid treatment varied between one single dose
and 8 weeks. The daily dose of steroids varied between
30 mg and 600 mg/kg (total 45 g) hydrocortisone (or
equivalent) (Fig. 1). In the high dose trials the daily doses
varied between 10 mg/kg (total 750 mg) and 600 mg/kg
(total 45 g) hydrocortisone (or equivalent). In the low
dose trials daily doses varied between 30 mg and 440 mg
hydrocortisone (or equivalent).
There was insufficient data to evaluate the outcomes
persistent dependence on haemodialysis and duration of
mechanical ventilation.
Bias risk assessment
Bias risk of trials was assessed according to The
Cochrane Handbook for Systematic Reviews of Interven-
tions (Fig. S2) [15]. Only two trials scored low risk of
bias in all domains. Therefore, we used the prespecified
group of trials with lower risk of bias in four domains. A
total of 16 studies were assessed to have lower risk of bias
(Fig. S2).
Effects of interventions
All pooled intervention effects with their 95 % CI of all
trials along with subgroup effects and all TSA are listed in
Table 2.
Comparison 1: steroids versus placebo or no intervention
Thirty-five trials randomised 4682 patients and evaluated
any dose of steroids in patients with sepsis. Two trials had
low risk of bias. We considered 16 trials to have lower
risk of bias.
All-cause mortality within longest follow-up. Thirty-one
trials (including 4290 patients) provided mortality data.
Mortality within longest follow-up was 37.6 % in the
steroids group and 41.0 % in the control group. Sub-
stantial heterogeneity was found (I2 = 54 %). There was
1225
no statistical significant difference (random-effects model
RR 0.89, 95 % CI 0.79–1.01; TSA-adjusted CI 0.74–1.08;
Figs. 2, S3). TSA on the two low risk of bias trials
appeared impossible because of insufficient data; the
conventional model showed no statistically significant
effect (Table 2). Subgroup analysis based on the pre-
specified lower risk of bias trials revealed no differential
effect. TSA of all trials (RRR 10 %; power 90 %) showed
that the accrued and the required information size were
far apart (Fig. S3) and that more than 17,000 additional
patients may need to be randomised before firm conclu-
sions can be drawn regarding the effect on mortality.
However, futility has been reached in our sensitivity trial
sequential analysis (RRR 20 %; power 80 %) (Fig. S3)
refuting a 20 % RRR to be shown with 80 % power.
Analyses stratified by risk of bias (Fig. 2), treatment
duration (long- compared to short-course steroids;
Fig. S4), severity of illness (SIRS and sepsis compared to
severe sepsis and septic shock; Fig. S5) and type of
steroids (excluding trials using dexamethasone) all
showed no statistically significant effects (Table 2) and
were in line with the other analyses suggesting that many
more patients need to be randomised before firm con-
clusions may be drawn.
Serious adverse events excluding mortality. No statisti-
cal difference was found in serious adverse events
including all trials that evaluated steroids for sepsis
(random-effects model RR 1.02, 95 % CI 0.92–1.15;
TSA-adjusted CI 0.7–1.48; Fig. 3, S6). TSA showed that
nearly 50,000 additional patients may need to be ran-
domised before firm conclusions can be drawn on the
effect on serious adverse events (Fig. S6). The types of
serious adverse events are listed in Table S6. The inci-
dence of serious adverse events did not vary according to
the degree of sepsis (Table 2).
Fig. 1 Randomised clinical trials with mortality data showing for
each trial the hydrocortisone dose (on the first day) (white bars) and
the time interval from sepsis/septic shock onset until randomisa-
tion/start treatment (black bars); a high dose steroids ([500 mg
hydrocortisone or equivalent) and b low dose (B500 mg hydro-
cortisone or equivalent). When other steroids were used, the
equivalent hydrocortisone dose was calculated using the table in the
Oxford Handbook of Critical Care [17]. When doses were
expressed in milligrams per kilogram body weight, daily doses
were calculated assuming a body weight of 75 kg. The trials by
Hoffman [37], Klastersky [29], Scarborough [30], Schumer [43],
Snijders [40], Rinaldi [58], Ruolan [59] and Wan [31] did not
provide information on the time interval. The trials by Schumer
[43] and Sprung [44] included two intervention groups using
different doses of steroids: D dexamethasone, MP
methylprednisolone
1226
Other outcomes. Time-specific analyses of mortality
were conducted for 30-day (16 trials) and 90-day (two
trials) follow-up. We found no statistically significant
treatment effect when evaluating 30-day mortality (ran-
dom-effects model RR 0.96, 95 % CI 0.85–1.08; TSA RR
0.98, TSA-adjusted CI 0.83–1.17; point estimates were
different as a result of different handling of zero event
trials) (Fig. S7). Data for 90-day mortality were too sparse
to perform TSA-adjusted analysis; in a conventional
analysis no statistically significant effect was found
(random-effects model RR 0.36, 95 % CI 0.04–2.90)
(Fig. S8).
GRADE assessment considering risk of bias, incon-
sistency, imprecision and risk of publication bias showed
very low quality of evidence (Table S7).
Comparison 2: high dose steroids versus placebo
or no intervention
Fourteen trials (2624 patients) evaluated high doses
([500 mg hydrocortisone or equivalent) of steroids for
sepsis. Only one trial had low risk of bias in all domains
[20]. Six trials were considered to have lower risk of bias
(lower risk of bias in four domains). One trial did not
report mortality (Table 1) [28].
All-cause mortality within longest follow-up. Six trials
with lower risk of bias and seven trials with high risk of
bias evaluated mortality in 2537 patients at different
lengths of follow-up. No statistically significant beneficial













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































model RR 0.87, 95 % CI 0.70–1.07; TSA-adjusted CI
0.38–1.99; Fig. S9).
Analyses stratified by risk of bias (Fig. S9), severity of
illness (SIRS and sepsis compared to severe sepsis and
septic shock; Fig. S10) and type of steroids (excluding
trials using dexamethasone) all showed no statistically
significant effects (Table 2).
Serious adverse events excluding mortality. No statisti-
cal significant difference was found in the overall
Fig. 2 Forest plot of mortality at longest follow-up of all trials evaluating steroids for sepsis with subgroups according to risk of bias
(random-effects model)
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proportion of serious adverse events (random-effects
model RR 1.03, 95 % CI 0.90–1.17; TSA-adjusted RR
1.02, CI 0.70–1.48). No statistically significant differ-
ences were found in subgroups according to bias risk and
disease severity (Fig. S11, Table 2).
Other outcomes. Three trials with high risk of bias [29–
31] reported mortality at 30 days; no 90-day follow-up
data was reported (Table 2). There was no statistically
significant effect.
Error matrix plots were constructed for overview of all
availableevidence forhighdose steroids at aglance (Fig. S17).
GRADE assessment considering risk of bias, inconsistency,
imprecision and risk of publication bias showed very low
quality of evidence for all outcomes (Table S8).
Comparison 3: low dose steroids versus placebo
or no intervention
Twenty-one trials randomised 2058 patients for low dose
(B500 mg hydrocortisone or equivalent) steroids for
sepsis. There were large differences between the trials in
the time interval between sepsis onset and initiation of
steroids treatment: 2–72 h (Fig. 1). Only one trial applied
short-course low dose steroids [32].
All-cause mortality within longest follow-up. Only one
trial had low risk of bias in all domains [33]. Ten trials
with lower risk of bias (1315 patients) and eight trials
with high risk of bias (438 patients) evaluated mortality at
different lengths of follow-up. The overall pooled esti-
mate showed no statistical difference (random-effects
model RR 0.90, 95 % CI 0.77–1.05; TSA-adjusted CI
0.49–1.67) (Figs. 4, S12).
Analyses stratified by risk of bias (Figs. 4, S12), treatment
duration (long- compared to short-course steroids; Fig. S13),
severity of illness (SIRS and sepsis compared to severe sepsis
and septic shock; Fig. S14) and type of steroids (excluding
trials using dexamethasone) all showed no statistically signif-
icant effects (Table 2). Sensitivity analyses (TSA,RRR20 %;
power 80 %) based on lower risk of bias trials and separately
all trials evaluating severe sepsis and septic shock showed
futility for treatment with low dose steroids (Figs. S12, S14).
Fig. 3 Forest plot of serious adverse events of all trials evaluating steroids for sepsis with subgroups according to risk of bias (random-
effects model)
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Serious adverse events excluding mortality. Nine trials
(with 866 patients) evaluated serious adverse events. One
trial had low risk of bias [33]. Seven trials had lower risk
of bias. Data were too sparse to perform a TSA. A con-
ventional analysis found no statistically significant
intervention effect (random-effects model RR 0.96, 95 %
CI 0.73–1.27; Fig. S15). The incidence of serious adverse
events did not vary according to the degree of sepsis
(Table 2).
Mortality at 30 days. Thirteen trials (1479 patients)
evaluated mortality at 30-day follow-up. One trial had
low risk of bias [33]. Ten trials had lower risk of bias. No
significant benefit was found from steroids treatment
(random-effects model RR 0.91, 95 % CI 0.77–1.07; TSA
RR 0.94, TSA-adjusted CI 0.55–1.62; point estimates
were different as a result of different handling of zero
event trials; Fig. S16). Subgroup analysis based on bias
risk showed no differential effect. TSA estimated that
many more randomized patients are needed before firm
conclusions can be drawn. A sensitivity analysis (TSA,
RRR 20 %; power 80 %) showed futility for low dose
steroids treatment (Fig. S16).
Mortality at 90 days. The results of 90-day mortality in
low dose steroids are equal to the overall 90-day mor-
tality, since only trials that evaluated low dose steroids
provided data on 90-day follow-up.
Other outcomes. Error matrix plots were constructed for
overview of all available evidence for low dose steroids at
a glance (Fig. S18). Data suggest that there are consid-
erable risks of systematic errors (bias) and random errors
(large standard errors on average). GRADE assessment
considering risk of bias, inconsistency, imprecision and
risk of publication bias showed very low quality of evi-
dence for all outcomes (Table S9).
Discussion
We did not find evidence for a beneficial effect of an
intervention with steroids in patients with SIRS, sepsis,
severe sepsis or septic shock in this systematic review
with meta-analyses and TSA, including 35 randomised
trials with 4682 patients. High ([500 mg hydrocortisone
Fig. 4 Forest plot of mortality at longest follow-up of low dose steroids (B500 mg hydrocortisone or equivalent) use according to risk of
bias subgroups (random-effects model)
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or equivalent) and low dose (B500 mg hydrocortisone or
equivalent) steroids were evaluated in separate compar-
isons and no evidence of a beneficial effect was found.
Moreover, TSA suggested that more than 17,000 patients
need to be randomised before firm conclusions can be
drawn on any present or absent intervention effect with a
10 % RRR. Evidence has been reached to refute a 20 %
RRR with a power of 80 %.
Our conclusion contrasts with previous publications
suggesting beneficial effects associated with use of a long
course of low dose steroids [6]. Differences might be
explained by another search strategy and different analyses
with improved accounting for risks of systematic, design
and random errors. There is accumulating evidence that
random error plays an important role in premature con-
clusions of spurious significant findings [11]. In simulation
studies up to 30 % of premature declarations of significant
effects are in fact overestimations of intervention effects,
once sufficient evidence has been reached [34].
A substantial clinical heterogeneity existed between the
included trials, even after separation into high and low doses
of steroids. Within both high and low dose steroid groups
the administrated daily dose of steroids differed importantly
(Fig. 1). Moreover, there were substantial differences
regarding the time interval between sepsis onset and
administration of the first steroid dose, e.g. in antibiotic
therapy timing appears to be an essential feature for any
beneficial effect. Therefore, lack of both optimised dosing
and optimised timing might obscure potential beneficial
effects of steroids. As dexamethasone has no mineralocor-
ticoid activity, analyses were repeated excluding trials using
dexamethasone and results appeared to be similar (Table 2).
Retrospectively, our study protocol could have been
more specific on exclusion criteria for trials evaluating
patients with SIRS and sepsis. We excluded trials that
evaluated steroids for prevention of diseases and for
autoimmune diseases. We also excluded trials that eval-
uated steroids for treatment of localized oedema.
Furthermore, we only included trials that evaluated
patients with SIRS if the criteria for SIRS were explicitly
stated in the methods section of the report; however, SIRS
criteria may not predict patient important outcomes and
may be too inclusive. Although we reached consensus
through discussions, the inclusion of some trials can still
be discussed [20, 30, 31, 33, 35–40]. To test the
robustness of our conclusions, we therefore conducted
several sensitivity analyses by excluding these trials and
they all resulted in similar findings (Table 2).
Trial sequential analyses, an error matrix to evaluate
risks of errors and GRADE assessment add to the strength of
the conclusions. However, our systematic review mirrors the
lack of quality and quantity of the included randomised
clinical trials. The included trials fall short on bias protec-
tion, included numbers of patients and chosen outcomes.
Therefore, the evidence of steroids for sepsis (both high and
low dose) is characterized by high risks of both systematic
errors and random errors. We used wide inclusion criteria to
evaluate the effect of steroids in the broad spectrum of
disease. Although none of the analyses showed a statistically
significant effect, we cannot exclude a small beneficial
intervention effect of steroids in a specific subgroup.
Conclusion
In this systematic review with meta-analyses and TSA we
did not find any statistically significant beneficial effect
that could support propagating the use of steroids for
sepsis. Further, our TSA suggests that many thousands of
randomised patients are needed in order to change this
perspective. Therefore, steroids should no longer be rec-
ommended for patients with sepsis outside ongoing [27]
or future well-designed randomised clinical trials with
low risks of both systematic error and random error.
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